Overview

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to examine the efficacy and tolerability of short-term omega-3 fatty acids monotherapy in youth with Autism Spectrum Disorders (ASD). The investigators hypothesize that Omega-3 fatty acids will be efficacious in improving the core and associated features of ASD in youth, and that Omega-3 fatty acids monotherapy will be safe and well tolerated by youth with ASD. The secondary aim of this study is to examine the neuropsychological effect of Omega-3 fatty acids monotherapy in youth with ASD. The investigators hypothesize that omega-3 fatty acids will be efficacious in improving cognitive functions in youth with ASD.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital